/ LLY
Eli Lilly & Co. Reports Third Quarter with $1.18 EPS, Downgrades Guidance
Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market expectations.
October 30, 2024Stocks to Watch Today: Tesla, LLY, and Bank of America
Eli Lilly's stock surged on news of its diabetes drug while Tesla saw a modest gain following news of reduced EU tariffs. Meanwhile, BAC declined after Berkshire Hathaway sold a significant portion of ...
August 20, 2024Stocks to Watch Today: LLY, WBD, and AMAT
Eli Lilly (LLY) surged on strong Q2 earnings driven by GLP-1 drug sales, while Warner Bros. Discovery (WBD) plummeted following a massive $11.2 billion impairment charge.
August 08, 2024Eli Lilly and Company (LLY) Shines in Q2 with $11.30 B Revenue, 68% EPS Growth
Eli Lilly and Company (NYSE: LLY) has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion.
August 08, 2024Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain
Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.
July 19, 2024